Retinopathy Risk with Continued Semaglutide Therapy
Retinopathy does not progressively worsen with continued semaglutide therapy; any worsening is typically transient and occurs early during rapid glycemic improvement, particularly in patients with pre-existing moderate-to-severe retinopathy and poor baseline glucose control. The long-term benefits of improved glycemic control far outweigh this acute risk 1.
Understanding the Mechanism
The retinopathy complications observed with semaglutide are not due to a direct drug effect on the retina 2, 1. Instead, they represent a well-established phenomenon called "early worsening of diabetic retinopathy" (EWDR) that occurs with any therapy causing rapid, robust glucose reduction in vulnerable patients 1, 3. This same pattern has been documented for decades with intensive insulin therapy.
The FDA label for Ozempic (semaglutide) explicitly states: "Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy" 3. The 2-year SUSTAIN-6 trial showed retinopathy complications in 3.0% of semaglutide patients versus 1.8% placebo, but this risk was concentrated in patients with pre-existing retinopathy (8.2% vs 5.2%) rather than those without known retinopathy (0.7% vs 0.4%) 3.
Clinical Decision Algorithm
Before Starting Semaglutide:
Assess retinopathy status in all patients, particularly those with:
- Baseline HbA1c >10% (marked hyperglycemia)
- Known diabetic retinopathy of any severity
- Long diabetes duration (>10 years)
- Poor prior glycemic control
Obtain ophthalmology evaluation if any of the above risk factors are present 4
During Semaglutide Therapy:
- Monitor closely during the first 3-12 months when rapid A1C reduction occurs 1
- Arrange regular ophthalmology examinations so changes can be addressed promptly 1
- Continue semaglutide therapy unless sight-threatening complications develop, as glucose lowering remains essential 1
Key Distinction - Transient vs Progressive:
The 2022 Canadian Cardiovascular Society guideline explicitly clarifies: "The long-term benefits of glucose control on the eyes far outweigh any acute risk" 1. The 2025 ADA Standards of Care confirm that meta-analyses show no association between GLP-1 RA treatment and retinopathy per se, except through the association with rapid A1C reduction at 3-month and 1-year follow-up 4.
Evidence Quality and Nuances
Recent systematic reviews and meta-analyses provide reassuring data:
- A 2025 OHDSI network study of 810,390 semaglutide users found no increased risk of proliferative diabetic retinopathy compared to other diabetes medications 5
- A 2026 meta-analysis showed no statistically significant association between GLP-1 RA use and DR progression (pooled RR = 1.07,95% CI: 0.90-1.28) 6
- A 2025 JAMA Ophthalmology systematic review confirmed semaglutide was not associated with increased risk of eye disorders or diabetic retinopathy overall 7
Common Pitfalls to Avoid
Do not discontinue semaglutide based solely on early retinopathy changes during the first year of therapy—this represents expected EWDR, not progressive drug toxicity 1
Do not confuse early worsening with long-term risk—the mechanism is rapid glycemic improvement in vulnerable eyes, not ongoing retinal damage 1, 3
Do not withhold semaglutide from patients with cardiovascular or renal disease due to retinopathy concerns—the mortality and morbidity benefits are substantial 2, 1
Practical Management Strategy
For patients with pre-existing moderate-to-severe retinopathy:
- Ensure ophthalmology follow-up is established before starting semaglutide
- Use slower titration if clinically appropriate (though this is not proven to prevent EWDR)
- Schedule ophthalmology visits at 3-6 month intervals during the first year
- Continue therapy with close monitoring unless sight-threatening complications develop
For patients without known retinopathy:
- Standard screening per ADA guidelines (annual exams if any retinopathy present) 4
- Risk of new-onset retinopathy complications is minimal (0.7% vs 0.4% placebo) 3
The 2020 ACC expert consensus notes that "it is unclear if this is a direct effect of the drug or due to other factors such as rapid improvement in blood glucose control" 2, with subsequent evidence strongly supporting the latter explanation 1.